Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Open-Label, Dose Escalation Study of ANG1005 in Patients With Malignant Glioma

NCT00539344 is registered in ClinicalTrials.gov with Angiochem Inc as lead sponsor.

NCT NCT00539344
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00539344 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Open-Label, Dose Escalation Study of ANG1005 in Patients With Malignant Glioma
Lead sponsor
Angiochem Inc
Phase
Phase 1
Overall status
Completed
Start date
October 31, 2007
Completion date
March 31, 2010
Enrollment
63 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

recurrent or progressive malignant glioma